Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949845 · ClinicalTrials.gov registry record · Early Phase 1
Cytokine-Associated Depression and Social Pain
A Early Phase 1 study of Depression, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Study location
NCT00949845 is a Early Phase 1 study of Depression that has completed, run by University of California, Los Angeles. The trial reports 1 study location across 1 state.
The verdict
NCT00949845, a Early Phase 1 study of Depression, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1
- Study location
Study Summary
Recent research has demonstrated a relationship between depression and immune system activity, specifically proinflammatory cytokine activity. Although experimentally-induced immune activation leads to increases in depressed mood, the neural correlates associated with these changes have remained largely unexplored. Based on relationships between cytokine activity, depression, and heightened physical and social pain sensitivity, I propose to investigate the effect of proinflammatory cytokine activation on the neural correlates of socially painful experience that may contribute to depression. Our previous work has shown that the dorsal anterior cingulate cortex (dACC), typically associated with physical pain distress, also plays a role in the distressing feelings associated with social rejection or social loss. Moreover, recent pilot data has revealed that individuals with elevated levels of baseline proinflammatory cytokines report feeling more distressed and show more dACC activity during social rejection. To investigate the causal role that cytokines may play in the heightened social pain sensitivity that can contribute to depression, participants will be randomly assigned to receive either endotoxin (which increases proinflammatory cytokine activity) or placebo. Subsequently, participants will complete a neuroimaging study in which they will be rejected during an online ball-tossing game. We hypothesize that individuals exposed to endotoxin will report more social distress and depression following rejection and will show more dACC reactivity during rejection. The proposed study is the first to investigate the effect of systemic inflammation on neural reactivity related to social and affective processes that may increase the risk of depression.
Conditions Studied
Interventions
- DRUG Endotoxin
Study Locations (1)
California
- UCLA General Clinical Research Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00949845
The ClinicalTrials.gov registry entry for NCT00949845 describes a study currently listed as completed, categorized as Early Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Endotoxin is the first listed.
NCT00949845 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00949845 about?
NCT00949845 is a clinical study titled "Cytokine-Associated Depression and Social Pain". Recent research has demonstrated a relationship between depression and immune system activity, specifically proinflammatory cytokine activity. Although experimentally-induced immune activation leads to increases in depressed mood, the neural correlates associated with these changes have remained lar...
What is the current status of trial NCT00949845?
This trial is currently completed. It is a Early Phase 1 study. The study started on 2007-01.
What conditions does trial NCT00949845 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00949845?
The interventions under investigation include: Endotoxin (DRUG).
Who is sponsoring clinical trial NCT00949845?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00949845 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
RECRUITING · Early Phase 1
-
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
RECRUITING · Early Phase 1
-
Probiotic Administration for Adolescent Depression
RECRUITING · Early Phase 1
-
Mood Effects of Serotonin Agonists: Depression
RECRUITING · Early Phase 1
-
Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.